XanthoPharm Welcomes Dr Fred Stevens
to its Scientific Advisory Board (SAB)
Weymouth, MA, June 18, 2021
XanthoPharm, a therapeutics company dedicated to developing novel therapeutics for the treatment of arrhythmias, welcomes Dr Fred Stevens to its SAB. Dr Stevens is world leading expert on dietary phytochemicals in human health and disease.
“It is an honor to officially welcome Dr Stevens as a member of our SAB,” said Bob Jenkins, CEO of XanthoPharm. “Dr. Stevens´ in-depth experience in phytochemicals, their formulation and monitoring, as well as performing clinical studies with them will be of significant help to our development. Additionally, his insights into regulatory issues regarding natural products will be invaluable to us.”
The SAB will be involved in strategic discussions related to our research, both clinical and pre-clinical, as well as our developmental strategy and pipeline.
About Fred Stevens
Dr. Jan Frederik (‘Fred’) Stevens is Principal Investigator at the Linus Pauling Institute, is Associate Dean for Research and Professor of Pharmaceutical Sciences, College of Pharmacy at Oregon State University in Corvallis. Dr. Stevens has authored more than 135 research articles in peer-review journals, 39 of which report on the chemistry and pharmacology of xanthohumol. He received five awards for excellence in teaching at the OSU College of Pharmacy.
About XanthoPharm
XanthoPharm is a therapeutics company dedicated to the development of xanthohumol for the treatment of arrhythmias in general and atrial fibrillation in particular. Atrial fibrillation(Afib) is the most common of all arrhythmias and its pharmaceutical management problematic. Our goal is to bring a therapeutic to Afib patients that is both efficacious and safe.